Maple-Brown Abbott Asian Investment Trust
The Fund is invested in companies listed (or expected to be listed) across Asia (ex-Japan) and is actively managed. We may also invest in companies listed outside Asia that conduct the majority of their operations in Asia.
Our value-based investment philosophy underlies our approach to stock selection, driven by our bottom-up research process designed to maximise the opportunities to deliver income and long-term capital growth to our clients. We utilise several valuation screens to rank our investment universe and generate stock ideas. Our experienced team then undertakes detailed quantitative and qualitative analysis to identify companies that are trading at a discount to our assessment of their underlying value.
The Fund provides exposure to a diversified portfolio of our highest conviction opportunities which we expect to deliver strong risk-adjusted returns over the long-term. We aim to invest across a broad universe of Asia (ex-Japan) companies and will typically hold 40–60 stocks.
The Fund aims to outperform the MSCI All Countries Asia Excluding Japan Net Index (AUD), after fees, over a four-year period.
|Inception date25/10/2002||Distribution frequencyQuarterly|
|BenchmarkMSCI All Countries Asia Excluding Japan Net Index (AUD)||Minimum initial application$ 20,000|
|APIR codeMPL0003AU||Management fees and costs %*^1.08|
|Pricing frequency & cut-offDaily/2pm Sydney time on a Business Day||Buy/Sell spread %^0.24/0.24|
A team of experienced and dedicated investment professionals.
Head of Asia
as at 30/11/2023
|1 mth %||3 mths %||1 yr % p.a.||3 yrs % p.a.||4 yrs % p.a.||5 yrs % p.a.||Since inception % p.a.*|
^Past performance is not a reliable indicator of future performance. No warranty can be given for future performance. Returns are volatile and may fluctuate quickly and significantly. Total return is based on the movement in net asset value per unit plus distributions and is before tax and after all fees and charges. Foreign tax credits are not included in the performance figures.
Source: Maple-Brown Abbott and MSCI
*Inception date is 25 October 2002.
The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com)
as at 07/12/2023
|Application price||Net asset value||Redemption price|
|$ 0.9547||$ 0.9524||$ 0.9501|
Forms and fund information
The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned MPL0003AU November 2023) referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.
Interested in investing with us?